Table 1.
List of studies on the combination of SBRT and immunotherapy in many cancers.
| Author | Disease | N | RT | ICI | Schedule | Abscopal Effects |
|---|---|---|---|---|---|---|
| Twyman Nature [33] | Melanoma | 22 | 6Gy x 2-3 8Gy x 2-3 (One Site) |
Ipilimumab 3mg/kg/3w x4 | Ipilimumab 3-5 days after RT | PD: 64% SD: 18% PR: 18% CR: None |
|
| ||||||
| Hiniker IJROBP 2016 [34] | Melanoma | 22 | 8Gy x 3 4Gy x 10 (1-2 Sites) |
Ipilimumab 3mg/kg/3w x4 | RT within 5 days of Ipilimumab | SD: 23% PR: 14% CR: 14% |
|
| ||||||
| Tang CI. Can Res 2017 [35] | NSCLC, colorectal cancer (CRC), RCC, Others | 35 | 12Gy x 4 6Gy x 10 (1 Site) |
Ipilimumab 3mg/kg/3w x4 | RT 1 day after Ipilimumab or 1 week after 2nd Ipilimumab | PR: 10% SD: 23% CR: None |
|
| ||||||
| Luke JCO 2018 [36] | Ovarian, Endometrial, CRC, Others | 73 | 30-50Gy (3-5, 2-4 Sites) | Pembrolizumab 200mg/3 weeks until progression, death, or toxicity | Pembrolizumab 7 days after SBRT | PD: 38 SD: 21 PR: 8 CR: 1 |